Achilles Therapeutics PLC (ACHL)
1.03
0.00 (0.00%)
USD |
NASDAQ |
Nov 05, 16:00
1.03
0.00 (0.00%)
After-Hours: 18:13
Achilles Therapeutics Enterprise Value: -53.00M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | -53.00M |
| November 01, 2024 | -53.20M |
| October 31, 2024 | -54.02M |
| October 30, 2024 | -53.20M |
| October 29, 2024 | -54.22M |
| October 28, 2024 | -54.43M |
| October 25, 2024 | -54.84M |
| October 24, 2024 | -54.84M |
| October 23, 2024 | -54.03M |
| October 22, 2024 | -54.23M |
| October 21, 2024 | -54.35M |
| October 18, 2024 | -54.02M |
| October 17, 2024 | -54.43M |
| October 16, 2024 | -54.43M |
| October 15, 2024 | -54.64M |
| October 14, 2024 | -54.64M |
| October 11, 2024 | -54.49M |
| October 10, 2024 | -54.97M |
| October 09, 2024 | -54.02M |
| October 08, 2024 | -53.20M |
| October 07, 2024 | -53.61M |
| October 04, 2024 | -52.95M |
| October 03, 2024 | -53.20M |
| October 02, 2024 | -54.42M |
| October 01, 2024 | -54.02M |
| Date | Value |
|---|---|
| September 30, 2024 | -53.20M |
| September 27, 2024 | -53.41M |
| September 26, 2024 | -54.76M |
| September 25, 2024 | -55.87M |
| September 24, 2024 | -56.08M |
| September 23, 2024 | -55.03M |
| September 20, 2024 | -52.38M |
| September 19, 2024 | -56.49M |
| September 18, 2024 | -65.94M |
| September 17, 2024 | -66.02M |
| September 16, 2024 | -66.10M |
| September 13, 2024 | -65.41M |
| September 12, 2024 | -65.94M |
| September 11, 2024 | -66.35M |
| September 10, 2024 | -65.73M |
| September 09, 2024 | -65.53M |
| September 06, 2024 | -65.53M |
| September 05, 2024 | -65.91M |
| September 04, 2024 | -66.14M |
| September 03, 2024 | -65.97M |
| August 30, 2024 | -65.53M |
| August 29, 2024 | -64.85M |
| August 28, 2024 | -65.65M |
| August 27, 2024 | -64.20M |
| August 26, 2024 | -64.20M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-157.05M
Minimum
May 09 2022
566.38M
Maximum
Apr 06 2021
-57.05M
Average
-94.23M
Median
Enterprise Value Benchmarks
| Autolus Therapeutics PLC | 182.82M |
| Biodexa Pharmaceuticals PLC | -2.612M |
| Centessa Pharmaceuticals PLC | 1.826B |
| Adaptimmune Therapeutics PLC | 18.55M |
| Verona Pharma PLC | 2.817B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.38M |
| Total Expenses (Quarterly) | 17.80M |
| EPS Diluted (Quarterly) | -0.41 |
| Earnings Yield | -154.4% |